Literature DB >> 12058880

Treatment of acute ischemic stroke: recent progress.

Norio Tanahashi1, Yasuo Fukuuchi.   

Abstract

Intravenous thrombolysis with tissue plasminogen activator is currently the most effective treatment of acute ischemic stroke if administerd within 3 hours after symptom onset. Intraarterial thrombolysis by prourokinase is the another choise if the middle cerebral artery is occluded and within less than 6 hours after onset. Although heparin especially a moderate dose is not proved to be effective, a randomized, placebo-controlled trial to determine the safety and efficacy of argatroban (a selective thrombin inhibitor) in patients with acute ischemic stroke was started in USA. Aspirin provides some benefit to patients with acute stroke. However, its effect is not fully satisfactory. Although reports of numerous trials for neuroprotective drugs have been disappointing, edaravone (free radical scavenger) was approved for the treatment of acute ischemic stroke in Japan. In the future, thrombolytic and neuroprotective drugs will be used in combination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12058880     DOI: 10.2169/internalmedicine.41.337

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

Authors:  Paul A Lapchak
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

2.  Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.

Authors:  Vaibhav Gaur; Anil Kumar
Journal:  Inflammopharmacology       Date:  2011-08       Impact factor: 4.473

3.  Expression of full-length human pro-urokinase in mammary glands of transgenic mice.

Authors:  Yaroslav Gursky; Robert Bibilashvili; Mikchail Minashkin; Alex Krasnov; Alex Deikin; Tatyana Ermolkevich; Andrey Popov; Lilia Verbovaya; Nicolai Rutkevich; Alexsander Shevelev; Sofia Georgieva; Sergey V Razin; Igor Goldman; Elena Sadchikova
Journal:  Transgenic Res       Date:  2009-04-25       Impact factor: 2.788

4.  A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects.

Authors:  Hidetoshi Shimizu; Shinsuke Inoue; Mai Endo; Yoshinobu Nakamaru; Kaori Yoshida; Tomoko Natori; Masae Kakubari; Makoto Akimoto; Kazuoki Kondo
Journal:  Clin Pharmacol Drug Dev       Date:  2020-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.